Premium
Increased platelet aggregation responses to 5‐hydroxytryptamine in patients taking chlorpromazine.
Author(s) -
Boullin DJ,
Woods HF,
Grimes RP,
GrahameSmith DG
Publication year - 1975
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1975.tb00468.x
Subject(s) - chlorpromazine , platelet , platelet aggregation , pharmacology , serotonin , in vivo , medicine , endocrinology , anesthesia , biology , receptor , microbiology and biotechnology
1 The aggregation response of platelets induced by 5‐HT was greatly increased in psychiatric patients receiving chlorpromazine therapy when compared with normal volunteers and psychiatric patients not receiving chlorpromazine. 2 Platelet aggregation responses to ADP were normal during chlorpromazine therapy, but 5‐HT induced aggregation was increased in rate and the typical transient reversible response was converted to an irreversible response in all subjects. This was usually indistinguishable from the ADP response. 3 When chlorpromazine therapy was stopped, plasma concentrations of chlorpromazine, monodesmethylchlorpromazine and chlorpromazine sulphoxide fell rapidly within one week, whereas 5‐HT induced platelet aggregation responses became normal after three weeks. The enhanced responses returned when chlorpromazine therapy was re‐instituted. 4 It is possible that platelet aggregation responses to 5‐HT in vitro could prove to be a useful index of the pharmacological effect of chlorpromazine in vivo.